April 29, 2026
Blue Sea Capital and Kolos Partners completed a growth investment in Scout – a clinical trial services provider offering meeting management, travel, and logistics support for pharmaceutical, biotech, and medical device companies conducting clinical research – in early 2026. No press announcement was issued by either party.
Healthcare Dealflow identified the investment via Scout’s own About page, which was updated in January 2026 to reference the transaction, and confirmed it via Blue Sea Capital’s portfolio page, which was updated in late Q1 2026. Blue Sea Capital and Scout did not respond to requests for comment.
Scout, formerly known as Meeting Protocol Worldwide, rebranded in 2024 and serves clients across therapeutic areas and trial stages with customizable services spanning time zones and geographies. The company was founded in 1995 by Patricia “Pat” Bingham and is currently led by CEO Moisha Platto, with Paige Bingham serving as Executive Chairman of the Board. Financial terms were not disclosed.
The investment reflects broader PE interest in clinical trial services, as sponsors and CROs increasingly look to third-party providers to manage the logistical complexity of multinational trials amid rising development costs and growing trial complexity.
Healthcare Dealflow’s The Daily Brief delivers healthcare deal activity, news, and analysis to your inbox every business day. Join the investment banks, private equity firms, and advisors who rely on it to stay current. Subscribe to The Daily Brief →